Enhabit, Inc. (EHAB) - Stock Analysis
Last updated: Mar 15, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
An agreed all-cash buyout at $13.80/share by Kinderhook, improving Q4 cash flow, and a recent ~30% deal-driven jump make Enhabit an event-arbitrage opportunity with potential spread compression toward the deal price as litigation and process milestones around the March 4â5 earnings window unfold.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong gross margin ⢠Elevated leverage ⢠Volatile profitability EHAB is cash-generative with strong gross margins and positive FY EBITDA/free cash flow but shows rising solvency and profitability risk driven by a Q4 net loss, high debt and intangibles, and tight operating leverage.
Price Behavior
Key Price Behavior Insights: ⢠Above last month SMA ⢠Tight midâ$13s range ⢠Rapid breakout rally Support Level: $13.58â$13.62 (secondary support ~$11.00â$11.30) Resistance Level: $13.66 EHAB is trading above its last month SMA (~$12.91) after a sharp rally from ~$11.09 to $13.62 (+~23%), facing immediate resistance near $13.66 with tight support around $13.58â$13.62 but vulnerable to a meanâreversion pullback if it loses the midâ$13s.
Sentiment & News
Key News Insights: ⢠PE buyout ⢠Shareholder suits ⢠Q4 met estimates Enhabit agreed to be acquired by Kinderhook for $13.80/share (~$1.1B), sparking a 22.6% rally, multiple shareholder lawsuits over deal fairness, and Q4 results that met expectations.
AI Summary
EHAB's investment case has shifted from an operational turnaround to a transaction-and-capital-structure storyânearâterm upside is capped by the Kinderhook $13.80 bid and attendant litigation while the key actionable opportunity is whether FYâ2025 FCF convertibility and stabilization of homeâhealth unit revenue/margins (and receivables collectability) can justify a higher takeâprivate valuation or a sustainable deleveraging path, so watch court outcomes, FCF persistence, and payer/receivable trends closely.
Description
Enhabit, Inc. is a U.S. provider of home health and hospice care, offering clinical services such as skilled nursing, therapy, disease-specific care and hospice support that address medical, emotional and psychosocial needs. The company operates a network of home health and hospice agencies across multiple states and, as of March 2022, managed 252 home health and 99 hospice agencies in 34 states. Headquartered in Dallas, Texas, Enhabit was incorporated in 2014, changed its name in March 2022, and began operating as a standalone company in July 2022.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 26 | Mar 5 | EHAB | Enhabit, Inc. | An agreed all-cash buyout at $13.80/share by Kinderhook, improving Q4 cash flow, and a recent ~30% deal-driven jump make Enhabit an event-arbitrage opportunity with potential spread compression toward the deal price as litigation and process milestones around the March 4â5 earnings window unfold. | Closed | +0.1% |